Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.47 USD
Change Today +0.89 / 2.65%
Volume 238.1K
As of 12:48 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

insys therapeutics inc (INSY) Snapshot

Open
$32.86
Previous Close
$33.58
Day High
$34.96
Day Low
$32.70
52 Week High
08/5/15 - $46.17
52 Week Low
09/15/14 - $15.45
Market Cap
2.5B
Average Volume 10 Days
820.6K
EPS TTM
$0.57
Shares Outstanding
71.8M
EX-Date
--
P/E TM
59.9x
Dividend
--
Dividend Yield
--
Current Stock Chart for INSYS THERAPEUTICS INC (INSY)

Related News

No related news articles were found.

insys therapeutics inc (INSY) Related Businessweek News

No Related Businessweek News Found

insys therapeutics inc (INSY) Details

Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets Subsys, a proprietary sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients; and Dronabinol SG Capsule, a dronabinol soft gelatin capsule that is generic equivalent to Marinol, an approved second-line treatment for chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. Its products candidates also include Dronabinol Oral Solution, a proprietary orally administered liquid formulation of dronabinol. The company is headquartered in Chandler, Arizona.

382 Employees
Last Reported Date: 03/3/15

insys therapeutics inc (INSY) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $889.2K
Chief Financial Officer
Total Annual Compensation: $383.0K
General Counsel and Corporate Secretary
Total Annual Compensation: $315.5K
Compensation as of Fiscal Year 2014.

insys therapeutics inc (INSY) Key Developments

U.S. Food and Drug Administration Accepts NDA Filing for Insys Therapeutics' Dronabinol Oral Solution

Insys Therapeutics announced that its new drug application for its proprietary Dronabinol Oral Solution has been accepted for filing by the U.S. Food and Drug Administration. The Dronabinol Oral Solution NDA requests FDA approval for anorexia associated with weight loss in patients with AIDS, and nausea, vomiting associated with cancer chemotherapy. The Prescription Drug User Fee Act goal date for the decision on the NDA is April 1, 2016, which reflects a standard review by the agency.

INSYS Therapeutics, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

INSYS Therapeutics, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. Net revenue for the second quarter of 2015 was $77.6 million compared to $55.7 million for the second quarter of 2014, an increase of 39%. Net income for the second quarter of 2015 was $7.3 million, or $0.10 per diluted share, compared to net income of $9.5 million, or $0.13 per diluted share, for the second quarter of 2014. Non-GAAP adjusted net income for the second quarter of 2015 was $15.6 million, or $0.21 per diluted share, compared to non-GAAP adjusted net income of $20.9 million, or $0.29 per diluted share, in the prior year quarter. Income from operations was $12 million against $15.2 million reported last year. Income before income taxes was $12.1 million against $15.2 million reported last year. EBITDA was $13.3 million against $15.8 million reported last year. Adjusted EBITDA was $19.8 million against $21.5 million reported last year. Adjusted income before income taxes was $18.6 million against $20.9 million reported last year. For the six months, the company reported net income of $15.3 million or $0.20 per diluted share on net revenue of $148.4 million compared to net income of $17.1 million or $0.23 per diluted share on net revenue of $97.3 million reported in the same period last year. Adjusted net income was $39.1 million or $0.52 per diluted share against $36.1 million or $0.49 per diluted share reported last year. Income from operations was $23.6 million against $27.9 million reported last year. Income before income taxes was $23.8 million against $27.9 million reported last year. EBITDA was $26.1 million against $29 million reported last year. Adjusted EBITDA was $44.3 million against $37.15 million reported last year. Adjusted income before income taxes was $42.1 million against $36.1 million reported last year.

INSYS Therapeutics, Inc. to Report Q2, 2015 Results on Aug 06, 2015

INSYS Therapeutics, Inc. announced that they will report Q2, 2015 results at 10:00 AM, Eastern Daylight on Aug 06, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INSY:US $34.47 USD +0.89

INSY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ARIAD Pharmaceuticals Inc $7.98 USD +0.4101
Array BioPharma Inc $5.62 USD -0.15
Depomed Inc $26.49 USD -0.13
Seattle Genetics Inc $39.91 USD +0.62
Spectrum Pharmaceuticals Inc $6.32 USD -0.05
View Industry Companies
 

Industry Analysis

INSY

Industry Average

Valuation INSY Industry Range
Price/Earnings 70.3x
Price/Sales 9.0x
Price/Book 12.0x
Price/Cash Flow 67.9x
TEV/Sales 8.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSYS THERAPEUTICS INC, please visit www.insysrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.